Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.320
+0.090 (2.79%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $341.94 million as of October 15, 2026. It is the 17,391st most valuable company in the world and the 3,063rd biggest in the United States. Its market cap has increased by 245.49% in one year.
Market Cap
341.94M
Enterprise Value
207.84M
1-Year Change
245.49%
Global Rank
Country Rank
#3,063 United States
Category
ChartMarket Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $341.94M, a decrease of -57.61%. That is a compound annual growth rate of -13.21%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 15, 2026 | 341.94M | 43.10% |
| Dec 31, 2025 | 238.95M | 147.03% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Editas Medicine | 375.50M |
| Galectin Therapeutics | 372.14M |
| Eikon Therapeutics | 363.99M |
| Scribe Therapeutics | 361.97M |
| Relmada Therapeutics | 358.41M |
| Fennec Pharmaceuticals | 356.98M |
| Kyverna Therapeutics | 356.84M |
| Opus Genetics | 352.75M |